Thoracic cancer

Researchers are testing a cell therapy made from healthy donor immune cells that are gene edited with CRISPR-Cas9 and engineered to target CD19, a marker on B-cell lymphomas. The trial enrolls about 30 adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. Phase 1 chec…

Researchers are testing whether giving adebrelimab, apatinib mesylate, and chemotherapy before surgery helps people with limited-stage small cell lung cancer. The study enrolls adults with early-stage disease that surgeons can remove. Participants receive the drug combination for…

Researchers are testing a new CAR-T cell therapy called C402-CD19-CAR in adults with large B-cell lymphoma that has come back or stopped responding to treatment. The therapy is made from each participant's own T cells, which are modified to target CD19, a marker on lymphoma cells…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This phase 3 trial tests whether adding the targeted drug inavolisib to standard maintenance therapy (Phesgo) can delay cancer growth in people with a specific genetic mutation (PIK3CA) in HER2-positive advanced breast cancer. About 230 participants who have already completed ini…

Researchers are testing whether a one-week course of partial breast irradiation works as well as a three-week course in women with low-risk early breast cancer who had breast-conserving surgery. The trial enrolls about 818 women and randomly assigns them to either 26 Gy in 5 trea…

Researchers are testing whether adding stereotactic ablative radiotherapy (SABR) to standard systemic therapy helps people with oligometastatic breast cancer, meaning cancer that has spread to only a few sites. The trial enrolls adults with 1 to 5 metastases in up to two organs. …

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

Researchers are testing whether women with cN3 breast cancer, a high-risk form, can safely skip an extra dose of radiation to lymph nodes that showed no visible cancer after chemotherapy. Normally, these nodes receive a boost of radiation after surgery. The trial randomly assigns…

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This early-phase study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard therapies. The main goals are to check the drug's safety and find the right dose, while also seeing if …

This Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

Researchers are testing whether adding simvastatin, a common cholesterol drug, to standard chemotherapy helps women with triple negative breast cancer. The trial enrolls 26 women with advanced triple negative breast cancer who are scheduled for eight cycles of AC-T chemotherapy. …

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This study tests whether the drug elacestrant can clear traces of cancer DNA found in the blood of people with hormone receptor-positive breast cancer who are at risk of late recurrence. About 50 adults whose blood tests positive for tumor DNA but show no visible spread will take…

This phase 2 trial is testing the immunotherapy drug pembrolizumab, given alone or with chemotherapy, in 318 Black patients with advanced non-small cell lung cancer. The goal is to see how well these treatments work in real-world settings and to find biological markers that predi…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This Phase 2 trial tests whether adding trilaciclib to the chemotherapy drug lurbinectedin can reduce severe neutropenia (a dangerous drop in white blood cells) in people with small cell lung cancer that has spread. About 30 participants will receive both drugs intravenously. The…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This study is testing whether a shorter, higher-dose radiation treatment (APBI) given over just three days is safe and effective for women with early-stage breast cancer or DCIS who have had a lumpectomy. The goal is to see if this approach causes fewer or milder side effects com…

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This pilot study tests a device that uses short, high-frequency electrical pulses to shrink or destroy soft tissue tumors in people with metastatic breast cancer. The trial will enroll 20 adults with tumors near the skin that are at least 1 cm but no larger than 5 cm. The main go…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…

This phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…

This phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This study tests a drug called NBTXR3 given with radiation therapy for people with locally-advanced non-small cell lung cancer who cannot have chemotherapy or surgery. The goal is to see if the combination is safe and helps control the cancer. About 40 adults with stage I to III …

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormon…

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

Researchers are testing whether dalpiciclib, a targeted cancer drug, combined with toremifene, a hormonal therapy, can slow the growth of advanced HR-positive, HER2-negative breast cancer when used as a first-line treatment. The trial plans to enroll 36 women who have not yet rec…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side e…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This study tests whether taking special gut bacteria capsules (RMT) alongside standard chemotherapy and immunotherapy can help control advanced lung cancer. About 82 people with untreated non-small cell lung cancer will receive either RMT or a placebo. The goal is to see if the b…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This study tests a technique called systematic margin shaving during breast-conserving surgery for breast cancer. The idea is to remove a thin extra layer of tissue around the tumor right after the main lump is taken out, based on a pathologist's check. Researchers want to see if…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a p…

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This study is for women aged 51 or older whose breast cancer has returned or who have a new cancer in the same breast. The goal is to see if giving a focused, short course of radiation before surgery is safe and effective enough to allow breast-conserving treatment instead of mas…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

Researchers at Emory University are testing intensity-modulated proton therapy (IMPT) for people with small cell lung cancer. Proton therapy delivers radiation to tumors while reducing exposure to nearby healthy organs like the heart. The study enrolls 30 adults with limited or e…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This phase II trial tests whether a drug called BIO 300, made from a soy compound, can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will receive BIO 300 along wi…

This study tests an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the drug osimertinib (Tagrisso) in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The gene therapy delivers…

This study tests whether using a chat-based mobile app (Zalo) can help people follow through with recommended tests after an abnormal chest X-ray read by AI. About 2,692 adults in Vietnam at risk for lung cancer or TB will be randomly assigned to receive either standard results o…

This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults w…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …

This phase 2 trial tests proton beam radiation therapy in 20 adults with non-small cell lung cancer that has spread to chest lymph nodes (N2) and has been surgically removed. Proton therapy targets cancer cells while sparing healthy tissue, potentially reducing recurrence risk. R…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…

This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then giv…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study looks at whether eating a Mediterranean diet (rich in vegetables, fruits, nuts, fish, and olive oil) can improve gut health, quality of life, and treatment outcomes for women with early breast cancer undergoing chemotherapy. About 105 participants will be randomly assi…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

This phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

Researchers are testing a radiation schedule that delivers higher doses per session and more sessions per day for non-small cell lung cancer that grows quickly. The trial enrolls adults with confirmed high-proliferation NSCLC who are planned for chest radiotherapy, regardless of …

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This trial tests whether adding an experimental drug called culmerciclib to standard hormone therapy can shrink tumors more effectively in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Participants receive either the combination or hormone therap…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests a device called SAVI Scout MD, which uses tiny radar reflectors placed in the breast before surgery to help surgeons locate and remove tumors more precisely. The goal is to see if this method leads to complete tumor removal with clear margins, potentially reducin…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This study tests a new drug called BGB-43395 combined with letrozole against standard CDK4/6 inhibitor drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole for people with advanced or metastatic HR+/HER2- breast cancer who have not had prior treatment for advanced disea…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer (ER+/HER2-) that has spread to lymph nodes and has a high chance of returning. About 4,220 participants will be randomly assigned to receive either…

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. Abou…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

Researchers are testing two experimental oral drugs, TT-10 and TT-4, in adults with advanced solid tumors such as kidney, prostate, and lung cancers that have worsened after standard treatment or cannot receive it. The drugs block adenosine receptors, which tumors use to quiet th…

This study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study compares a new experimental drug, BL-M07D1, to an approved therapy (DS-8201) in people with a common form of advanced breast cancer (HR-positive, HER2-low). The goal is to see if the new drug can delay cancer growth or improve survival. About 120 women aged 18 to 75 wi…

This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

Inavolisib treats certain PIK3CA-mutated, HR-positive, HER2-negative breast cancers but can raise blood sugar. Researchers at Tianjin Medical University Cancer Institute and Hospital are studying whether matching blood sugar monitoring and preventive metformin to each patient's r…

This study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enrol…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune response to the drug pembrolizumab in people with metastatic or locally advanced triple negative breast cancer. About 30 participants will be randomly assigned to receive either the combinat…

This study follows 138 adults in Bulgaria and Slovenia with HER2-low advanced breast cancer who are taking trastuzumab deruxtecan (T-DXd), a targeted therapy. Researchers will track how long patients go before needing a different treatment or dying. The goal is to see how well T-…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study compares two types of radiation therapy for women with early-stage breast cancer who have had a lumpectomy. One group receives radiation to the whole breast, the other only to the area where the cancer was removed. Both treatments are given once a day for about one wee…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This study tests whether two experimental drugs (livmoniplimab and budigalimab) combined with chemotherapy work better than the current standard treatment (pembrolizumab plus chemo) for people with untreated metastatic non-squamous non-small cell lung cancer. About 840 adults wil…

This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the co…

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

Researchers are testing whether adding the drug inavolisib to hormone therapy and the antibody combination trastuzumab plus pertuzumab helps shrink HER2-positive, HR-positive breast tumors before surgery. The trial enrolls 170 patients with early-stage breast cancer that has a PI…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.

This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

This early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

Researchers are testing whether adding tislelizumab and anlotinib after chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without their cancer coming back. The study enrolls adults aged 18 to 75 whose cancer has not worsened after concurrent …

Researchers are testing whether treating a few growing spots of metastatic breast cancer with surgery, radiation, or heat ablation while continuing the same systemic drug can keep the cancer under control longer. The trial enrolls people with metastatic breast cancer whose cancer…

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This study tests a drug called sotorasib in people with advanced non-small cell lung cancer that has a specific change in the KRAS gene (called G12C). Participants have not yet received any treatment for their advanced cancer. The goal is to see if sotorasib is safe and effective…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests a new gene therapy (quaratusugene ozeplasmid) plus an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive stage small cell lung cancer. The goal is to see if the combination can keep the cancer from growing longer than standard ca…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effe…

Researchers are testing whether combining SX-682, an experimental drug that blocks CXCR1 and CXCR2, with proton craniospinal irradiation is safe and effective for people with leptomeningeal disease from melanoma or non-small cell lung cancer. Participants take SX-682 by mouth twi…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…

This study tests whether a new quarterly injection of letrozole delivers the same amount of medicine into the body as the standard daily pill. It involves 120 postmenopausal women who have already completed at least 4-5 years of hormone therapy for early breast cancer. The goal i…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants w…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…

This early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study firs…

This phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-stage trial is testing an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in people with locally advanced or metastatic breast cancer and other solid tumors. The study aims to find the safest dose and understand how the drug b…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This early-stage study tests a new drug called TQB2922, given as a shot under the skin, in 42 people with advanced non-small cell lung cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elace…

This phase 3 trial compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. Participants will receive toripalimab either before surgery (neoadjuvant), after surgery (adjuvant), or bo…

This phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants wil…

This Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib can help people with a certain type of Stage III lung cancer stay cancer-free longer. Participants must have an EGFR gene mutation and have already completed chemotherapy and radiation without …

Researchers are testing whether combining pembrolizumab, an immunotherapy given intravenously every three weeks, with lenvatinib, a daily oral drug, can help adults with metastatic non-small cell lung cancer that carries a RET gene rearrangement and has worsened after prior treat…

This study is a safety check required by Korean health authorities after capivasertib was approved for breast cancer. Researchers will watch for side effects and see how well the drug works in everyday medical practice. About 130 patients in Korea who are already prescribed the d…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

Researchers are testing whether adding the blood pressure drug olmesartan to dalpiciclib and standard hormone therapy helps women with HR+/HER2- advanced breast cancer. The trial enrolls 40 women aged 18 to 75 with locally advanced or metastatic disease. Everyone receives the thr…

This Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This trial studies people with early-stage non-small cell lung cancer who are having surgery to remove the tumor. During surgery, doctors usually also remove lymph nodes from a specific area called station 4L. The trial randomly assigns half of the participants to have those lymp…

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…

Researchers are testing whether a single, concentrated dose of radiation to the tumor site can replace the usual weeks of daily radiation after breast-conserving surgery. The trial enrolls 250 women with early-stage, low-risk breast cancer that has not spread to lymph nodes. Doct…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase study tests a new cell therapy called NK510 in 12 people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment uses specially designed natural killer cells that are blocked from a protein called TIGIT, aiming to boost …

This study tracks how well freezing breast tumors (cryoablation) works together with hormone therapy for women aged 70 and older with low-risk, early-stage breast cancer. Researchers will follow 400 participants for up to 5 years to see how often the cancer comes back. The goal i…

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) given after surgery works better than standard treatments to prevent breast cancer from coming back. It is for people with triple negative breast cancer who still have cancer cells in th…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …

This phase III trial is investigating whether surgically removing the primary lung tumor, in addition to continuing the targeted therapy osimertinib, can prolong the time before disease progression in patients with EGFR-mutant non-small cell lung cancer that has spread to a limit…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…

This study is testing two new blood tests designed to help doctors detect cancer in people who have symptoms that might be cancer. The study will involve 1,650 adults aged 45 and older who are already undergoing medical tests for possible cancer. The goal is to see how well these…

This study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…

Researchers are testing a radioactive tracer called 68Ga-DOTA-dPNE that binds to the CD73 protein on breast cancer cells. Women with breast cancer receive the tracer intravenously and then undergo PET/CT scans. The study checks how well the tracer detects tumors, bones, and lymph…

Researchers are testing whether a small implantable marker called Magseed, along with a handheld magnetic probe called Sentimag, can help surgeons locate and remove a specific axillary lymph node in breast cancer patients who have had chemotherapy before surgery. The study enroll…

This study is testing whether a breath test can detect breast cancer in women aged 40 to 74. Researchers will collect breath samples from over 5,000 women before their standard biopsy or MRI and compare the chemical patterns between those found to have cancer and those who do not…

Researchers are testing a new PET imaging tracer called 18F-HER2 Affibody to see how well it detects HER2-expressing breast cancer. The study includes 40 adults with confirmed or suspected HER2-positive breast cancer. Participants receive the tracer and then undergo a PET scan. T…

Researchers compare two tracers, indocyanine green (ICG) and blue patent dye, for locating lymph nodes during targeted axillary dissection in breast cancer patients who have received chemotherapy before surgery. The trial measures how often each tracer successfully identifies the…

This study is testing a new 3D automated ultrasound system called ATUSA to see how well it can image suspicious breast lesions. Up to 800 women with suspicious findings on standard imaging will get an ATUSA scan before their biopsy. The goal is to collect images and compare them …

This study looks at whether adding an MRI to the yearly mammogram can help find breast cancer earlier in women with dense breasts. Participants will have a mammogram and a risk score calculated from it. Those with a high risk score will be offered an MRI. The goal is to see if th…

Researchers are testing a system called Magseed Pro and Sentimag Gen3 to help surgeons find breast tumors and suspicious lymph nodes during surgery. The study enrolls 224 adults with breast cancer who need these areas marked and removed. Doctors place a small magnetic marker into…

This trial is testing whether advanced PET-CT scans can spot early signs of heart damage caused by standard radiation therapy for locally advanced non-small cell lung cancer. Ten adults with stage III lung cancer will receive a special PET-CT scan before and three months after th…

This study explores whether a biosensor using trained laboratory animals can detect non-small cell lung cancer (NSCLC) by smelling unique chemicals in urine. Participants include people with and without NSCLC, as well as those suspected of having it. The goal is to see if this an…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

Researchers are developing an artificial intelligence model that reads preoperative CT scans and clinical data to predict whether lung cancer associated with cystic airspaces has high-risk features. The study includes 600 patients with non-small cell lung cancer who had surgery a…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

The COGNITION study is a molecular diagnostic platform that collects tumor and blood samples from up to 2,000 adults with early breast cancer, including those receiving chemotherapy before surgery. Researchers perform comprehensive genomic sequencing on samples taken before and a…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This early-stage trial tests a new radioactive tracer called [68Ga]Ga DOTA-5G for PET/CT scans in 30 people with metastatic lobular breast cancer. The goal is to see if it can find cancer lesions better than current methods and to check its safety. Participants receive one inject…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

This study tests a new imaging agent called pHLIP ICG that makes breast cancer cells glow during surgery. The goal is to help surgeons see and remove all cancerous tissue more accurately. The trial involves 55 adults with early-stage breast cancer who have not had prior treatment…

This study is testing a new blood test to find early-stage lung cancer in heavy smokers who have no symptoms. Researchers will collect blood samples from 350 current or former smokers aged 30-80, including those with and without lung cancer. The goal is to see if the test can det…

Researchers are developing a blood test that uses DNA methylation patterns and machine learning to detect multiple types of cancer at an early stage. The PROFOUND study collects blood samples from people newly diagnosed with cancer and from people without a confirmed cancer diagn…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

Researchers at Indiana University are testing an educational program called ED-LCS that teaches emergency department patients about lung cancer screening. The study enrolls adults aged 50 to 80 who have smoked at least 20 pack years and quit within the past 15 years, making them …

This study is testing a new blood test that uses laser technology and artificial intelligence to help doctors tell apart high-risk and low-risk breast cancer patients. About 330 people with breast cancer will give a blood sample before treatment. The test looks at tiny particles …

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This study compares annual mammograms to a personalized screening schedule based on each woman's breast cancer risk. Participants choose or are assigned to either annual screening or risk-based screening, which uses genetic testing and personal history. The goal is to see if pers…

Cancer patients with a central catheter can develop a blood clot in the upper arm. After at least three months of standard blood-thinning treatment, this trial tests whether switching to a lower, preventive dose of apixaban can stop new clots from forming. Participants stay on th…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

Researchers are testing whether giving targeted radiation to lung tumors before a lung transplant can create an immune response that helps the body fight cancer. The trial enrolls adults with end-stage lung disease and hard-to-treat lung cancer who need a transplant. The goal is …

This early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This study tests a program to help long-term lung cancer survivors feel more socially connected and improve their quality of life. Thirty survivors will be randomly assigned to either the program or a comparison group. The program uses techniques from cognitive behavioral therapy…

Researchers at the University of Hong Kong are evaluating a survivorship program that sorts cancer patients into moderate or high needs after treatment. People with moderate needs receive weekly or bi-weekly e-intervention videos on managing distress and weight, with peer volunte…

This pilot study tests two surgical methods—targeted muscle reinnervation (TMR) and regenerative peripheral nerve interfaces (RPNI)—alone and together to reduce chronic and phantom limb pain in cancer patients who have had an amputation. About 45 adults will be randomly assigned …

Researchers are testing whether an AI-generated, personalized discharge plan improves the quality of discharge teaching and recovery for people who had lung cancer surgery. The trial enrolls 156 adults who had surgery for stage I to III lung cancer and are going home to recover. …

This study compares two approaches for breast cancer patients who still have cancer in their sentinel lymph node after chemotherapy: removing the underarm lymph nodes (surgery) or treating them with radiation. The goal is to see if radiation can reduce the risk of arm swelling (l…

This study tests whether a nerve block given through a small port under the skin can help control chest pain in people with advanced lung cancer. The block delivers numbing medicine near the chest wall nerves. Researchers will compare pain levels and side effects in 180 patients …

Researchers test whether an AI-supported mobile app helps breast cancer patients manage chemotherapy symptoms, feel more confident, and enjoy a better quality of life. Seventy women receiving chemotherapy for the first time join the study. Half use the app to report daily symptom…

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

Researchers are studying whether a supervised exercise program can protect the heart and improve fitness in women receiving chemotherapy for breast cancer. The trial enrolls women who are scheduled for chemotherapy before or after breast cancer surgery. Participants attend exerci…

This study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…

This study looks at whether combining resistance and aerobic arm exercises can improve arm strength, function, and quality of life in breast cancer patients. About 40 women who are at least 15 months past surgery and not currently active will participate. The goal is to find bett…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This trial tests whether personalized acupuncture—chosen together by the patient and clinician—can ease psychosomatic symptoms like anxiety, depression, sleep problems, and fatigue in women with breast cancer. Participants are divided into groups based on their symptom patterns a…

This pilot study tests whether a nurse-led, group-based virtual coping program called RESTORE is feasible and acceptable for people who have finished treatment for triple-negative breast cancer. The program teaches skills like problem-solving, relaxation, and mindfulness to help …

This study tests whether doing physiotherapy and using a mechanical stimulation device before breast reconstruction surgery can reduce shoulder pain and improve movement afterward. About 72 women scheduled for a specific type of breast reconstruction (using a back muscle flap) wi…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This study is testing whether a mobile app called Mighty Pro can help young women with breast cancer feel less distressed. The trial will include 120 women aged 18 to 45 who are patients at a specific cancer center. Participants will use the app for 26 weeks, and researchers will…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …

Researchers compare two robotic surgery approaches for removing lung tumors in adults with non-small cell lung cancer. Participants are assigned at random to either biportal surgery, which uses two incisions, or multiportal surgery, which uses several small ports. The study track…

Researchers are studying whether proton therapy is practical on a national scale and whether it reduces late side effects, such as second cancers and heart damage, compared with standard photon radiation. The trial enrolls adults with Hodgkin or non-Hodgkin lymphoma confined to t…

Researchers are studying whether nutritional support helps people with advanced lung cancer maintain their weight, strength, and quality of life during chemotherapy. The trial enrolls 100 adults with high nutritional risk. Participants receive dietary advice or a structured nutri…

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This pilot study tests a 4-week personalized exercise program for people aged 70 and older who are about to have cancer surgery. Participants follow daily exercises at home using a smartphone app. The goal is to see if this approach improves their physical fitness before the oper…

This study compares standard palliative radiation for lung tumors with a newer, more focused technique that delivers a higher dose while sparing the esophagus. The goal is to improve or maintain quality of life by better controlling symptoms and reducing side effects. About 141 a…

Cancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This pilot study is testing a combined program of mobile health exercise and cognitive rehabilitation for older cancer survivors (age 60+) who have concerns about memory or thinking after treatment. The program uses a smartphone app for exercise tracking and group workshops for b…

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…

This study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This trial tests whether pharmacopuncture, a treatment that injects small amounts of herbal medicine into acupuncture points, can reduce joint pain in women with breast cancer who take aromatase inhibitors. These drugs often cause joint pain, and the study compares pharmacopunctu…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This Spanish trial tests whether a 6-month exercise program (combining resistance and aerobic training) can improve quality of life in 74 early breast cancer patients taking hormone therapy. Half the participants will do the exercise program three times a week, while the other ha…

This study tests a 4-month coaching program called SONATA that helps older adults (age 60+) with advanced cancer build a support network of family and friends. The goal is to see if this social support makes it easier to stick with treatment and feel better. About 330 patients an…

This study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This study tests whether a wearable device and digital platform can help people recover better after lung cancer surgery. About 126 patients with non-small cell lung cancer will either use the wearable system or receive standard care. The system tracks heart rate, oxygen levels, …

Researchers are testing whether a home-based prehabilitation program can help older adults with non-small cell lung cancer prepare for surgery. The program combines aerobic exercise, breathing muscle training, functional and chest expansion exercises, nutrition guidance, and smok…

This study tests whether using a special dye (ICG) to map the arm's lymph vessels can make daily arm massage more effective at preventing lymphedema (swelling) after breast cancer surgery. 30 women will be randomly assigned to either ICG-guided massage or traditional massage, and…

This study tests an online, therapist-guided program to help cancer survivors who have anxiety, depression, or fear of cancer returning. About 400 adults in Sweden who finished cancer treatment at least 6 months ago will take part. The goal is to see which parts of the 10-week on…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study tests whether personalized patient navigation can help more American Indian and Alaska Native people in Washington state get screened for lung cancer. About 237 adults aged 50-77 who smoke or recently quit will be enrolled. The goal is to see if tailored support helps …

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …

This study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

Researchers are investigating whether metabolic markers measured by PET/CT scans and tumor tissue tests can predict how well early-stage non-small cell lung cancer responds to immunotherapy given before surgery. Thirty patients with stage IB to IIIA NSCLC that lacks EGFR and ALK …

This study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…

This study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study is testing whether a less invasive procedure called target axillary dissection (TAD) can accurately check for cancer spread in the lymph nodes of people with locally advanced breast cancer after chemotherapy. The goal is to see if TAD can replace more extensive lymph n…

This study is testing an online tool called MyMammogram that helps women ages 39-49 decide whether to get a mammogram. The tool also shares the woman's risk and preferences with her doctor before the visit. The goal is to see if this approach works well in rural healthcare settin…

Researchers at Portsmouth Hospitals NHS Trust and the University of Portsmouth want to know whether they can measure breast biomechanics in women treated for early breast cancer. The study includes 45 women who have had surgery, with or without radiotherapy, for cancer in one bre…

This observational study follows 50 adults with locally advanced or metastatic lung cancer who are starting chemotherapy or immunotherapy. Researchers want to see how cancer-related fatigue and daily physical activity change during treatment, and whether those changes are connect…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

Researchers are studying whether a blood test that looks for tiny traces of cancer DNA can identify early-stage lung cancer patients who are unlikely to need extra treatment after surgery. The trial enrolls adults with stage IB to IIIA non-small cell lung cancer who have had comp…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients using heart tests, blood samples, and questionnaires. The goal is to see if tailoring treatment based on individual risk can reduce heart problems.

This study follows 100 women with early-stage breast cancer who are receiving standard chemotherapy or anti-HER2 therapy. Researchers will use heart ultrasounds and blood tests to look for early signs of heart damage. The goal is to find better ways to detect cardiac side effects…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…

This study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study aims to understand why breast cancer risk and outcomes vary among different people. Researchers will collect blood, tissue, and survey data from 800 adults in South Florida, including those with suspicious breast findings or newly diagnosed breast cancer. By analyzing …

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

Surgeons use imaging-guided techniques to locate breast tumors they cannot feel, aiming to remove the cancer completely while sparing healthy tissue. This large observational study compares several methods, including wire-guided localization, intraoperative ultrasound, magnetic s…

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate t…

This study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…

This international registry follows people who took part in GBG clinical trials for early breast cancer, collecting health information long after those trials end. Researchers track survival, late side effects, and issues related to pregnancy, fertility, and quality of life. The …

Researchers are comparing three ways to check lymph nodes after chemotherapy in people with breast cancer that had spread to the lymph nodes but turned negative with treatment. The study follows 3,000 patients across multiple countries who receive either full lymph node removal, …

This study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…

This study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

Researchers are testing whether breast cancer patients who give consent digitally can reliably report complications after surgery using questionnaires. The study includes 50 women with early invasive breast cancer who are having breast-conserving surgery and a sentinel lymph node…

This study is testing whether a probiotic called BIOHM can change the community of bacteria and fungi (the microbiome) in the breast and gut of people with breast cancer. Researchers will measure certain biomarkers in 100 participants to see if the probiotic has an effect. The go…

This study reviews medical records from 600 lung cancer patients who had surgery between 2004 and 2019. The goal is to see if the use of robotic surgery has led to more atypical segmentectomies (removing part of a lung lobe). Researchers want to understand how robotic methods com…

Researchers are studying whether blood and tissue samples can show when metastatic breast cancer stops responding to standard first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The study enrolls women with ER-positive, HER2-negative metastatic breast cancer …

This study compares two types of minimally invasive lung cancer surgery: robotic-assisted (RATS) and video-assisted (VATS). It will follow 512 patients across Europe to see which technique leads to better quality of life and recovery. The goal is to help surgeons and patients mak…

This study enrolls 3,300 women with invasive breast cancer living in 59 North Carolina counties. It aims to understand how tumor biology, healthcare access, and patient behavior together affect outcomes. All participants receive a structured program to improve communication with …

This study is auditing a surgical technique called Targeted Sentinel Node Biopsy (TSNB) for breast cancer patients who have a small number of cancer cells in their lymph nodes. The goal is to see if this less invasive procedure can accurately identify cancer spread while causing …

This study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

This study is collecting blood samples from 170 people with metastatic breast cancer to look for ESR1 gene mutations, which can make cancer resistant to hormone therapy. Researchers will compare these blood-based results with standard tissue tests. The goal is to better understan…

Some cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This international registry collects data on women who have breast reconstruction with implants placed in front of the chest muscle (pre-pectoral) after mastectomy for breast cancer. Researchers follow participants for surgical complications, aesthetic results, cancer outcomes, a…

This study is testing whether it is safe for women aged 70 and older with small, screen-detected, ER+/HER2- breast cancers to simply monitor the tumor with regular ultrasounds instead of undergoing immediate treatment like surgery or radiation. The main goal is to see how many tu…

This study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are gi…

This study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…

This study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…

This study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can …

This study looks at whether a structured program can help more high-risk smokers get a first lung cancer screening with a CT scan. About 500 people aged 50 to 74 who smoke or recently quit will join. The goal is to see if a dedicated network makes screening easier and more effect…

This study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…

This study will map the location of small blood vessels in the chest wall using bony and soft tissue landmarks. The goal is to help surgeons perform partial breast reconstruction more precisely after breast cancer surgery. The study will involve 20 women undergoing elective breas…

Researchers at Lille University are following 350 people, including cancer patients recently diagnosed with breast, gynecological, testicular or digestive cancer, their caregivers, and healthcare professionals. Over one year, participants answer questionnaires about post-traumati…

This study tests a new way to mark the area where a breast tumor was removed, so radiation therapy can be more accurately aimed afterward. About 50 adults with early-stage breast cancer or a precancerous condition called DCIS will take part. The goal is to see if this marking hel…